Maegim한국어

앱클론

174900KOSDAQSector: Pharma & Biotech
₩19,870 3.78%Market cap ₩396.4BAs of Jul 21, 2026 close · updated once daily
C
Grade C43.2 ptsTop 66% of 2,523 stocks
Financial strength
48.7
Growth momentum
53.8
Price attractiveness
29.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

48.7
How much debt does it carry relative to equity?
Debt-to-equity ratio
17.1%
Above median · Top 18.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
492.2%
Above median · Top 26.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-374.1%
Below median · Top 86.6% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-29.6%
Below median · Top 73% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

2

Growth momentum

53.8
How much did revenue grow in a year?
Revenue growth (YoY)
101.5%
Above median · Top 8.9% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
11.4%
Above median · Top 28.8% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-13.1%
Below median · Top 65% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-101.6%
Below median · Top 82% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

29.3
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 61.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
6.56x
Below median · Top 80.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15